GoAI
Get started
Gelteq Limited Ordinary Shares logo

Gelteq Limited Ordinary Shares

GELS

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Regular session

$0.5456

+$0.0139 · +2.61%

Aug 25, 3:03 PM ETData delayed

GELS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

23

Expensive

Momentum

18

Strong Down

Sentiment

53

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
AU
CEO
Nathan Jacob Givoni
Listed since
Oct 29, 2024
Employees
18

Market position

Day range

Current $0.5456

52-week range

Current $0.5456

Open
$0.526
Previous close
$0.5317
Volume
33.88K
0.01× average
Average volume
3.73M
Average daily volume
Market cap
5.01M USD
Beta
-0.43
Market reference 1
50-day average
$0.6481
-15.82% below average
200-day average
$0.7567
-27.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.87M AUD
EV / EBITDA
-1.1×
Earnings yield
0.00%
Free cash flow yield
0.00%

Profitability & efficiency

Return on equity
-42.05%
Return on assets
-30.94%
Return on invested capital
-27.41%

Financial health

Current ratio
0.27×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends549%-1247%-3044%-4841%Gross margin, FY2022: 35.69%Gross margin, FY2023: 38.72%Gross margin, FY2025: 100.00%Operating margin, FY2022: -2164.39%Operating margin, FY2023: -3885.31%Operating margin, FY2025: -3317.65%Net margin, FY2022: -2283.44%Net margin, FY2023: -4391.39%Net margin, FY2025: -4011.86%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 35.69%. Gross margin FY2023 38.72%. Gross margin FY2025 100.00%. Operating margin FY2022 -2164.39%. Operating margin FY2023 -3885.31%. Operating margin FY2025 -3317.65%. Net margin FY2022 -2283.44%. Net margin FY2023 -4391.39%. Net margin FY2025 -4011.86%.

Income trends

Revenue

165.65K AUD+107.46%

Operating income

−5.5M AUD-86.54%

Net income

−6.65M AUD-87.40%
Income trends across reported periods846.75K AUD−1.88M AUD−4.6M AUD−7.33M AUDRevenue, FY2022: 147.54K AUDRevenue, FY2023: 79.84K AUDRevenue, FY2025: 165.65K AUDOperating income, FY2021: −647.62K AUDOperating income, FY2022: −3.19M AUDOperating income, FY2023: −3.1M AUDOperating income, FY2024: −2.95M AUDOperating income, FY2025: −5.5M AUDNet income, FY2021: −648.92K AUDNet income, FY2022: −3.37M AUDNet income, FY2023: −3.51M AUDNet income, FY2024: −3.55M AUDNet income, FY2025: −6.65M AUDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 147.54K AUD. Revenue FY2023 79.84K AUD. Revenue FY2025 165.65K AUD. Operating income FY2021 −647.62K AUD. Operating income FY2022 −3.19M AUD. Operating income FY2023 −3.1M AUD. Operating income FY2024 −2.95M AUD. Operating income FY2025 −5.5M AUD. Net income FY2021 −648.92K AUD. Net income FY2022 −3.37M AUD. Net income FY2023 −3.51M AUD. Net income FY2024 −3.55M AUD. Net income FY2025 −6.65M AUD.
Metric (AUD)FY2025FY2024FY2023FY2022FY2021
Revenue165.65K AUD—79.84K AUD147.54K AUD—
Cost of goods sold——48.93K AUD94.87K AUD—
Gross profit165.65K AUD—30.92K AUD52.66K AUD—
Research and development628.61K AUD276.06K AUD665.04K AUD529.02K AUD277.06K AUD
Selling, general, and administrative2.22M AUD1.27M AUD1.7M AUD1.55M AUD463.73K AUD
Operating expenses5.66M AUD2.95M AUD3.13M AUD3.25M AUD647.62K AUD
Interest expense1.89M AUD585.12K AUD403.52K AUD174.5K AUD1.3K AUD
Depreciation and amortization1.22M AUD1.21M AUD1.23M AUD1.22M AUD57.95K AUD
Operating income−5.5M AUD−2.95M AUD−3.1M AUD−3.19M AUD−647.62K AUD
Net income−6.65M AUD−3.55M AUD−3.51M AUD−3.37M AUD−648.92K AUD

Company facts updated Aug 25, 2026.

GELS news

globenewswire.com

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs

MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for pharmaceutical, animal…

Read source
globenewswire.com

Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications

MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company") today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin…

Read source
globenewswire.com

Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications

MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin…

Read source
globenewswire.com

Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion

MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will…

Read source

GELS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$444.17

+0.07%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$148.65

+1.30%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$553.72

+1.12%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$370.63

-0.79%

Sanofi logo

SNY

Sanofi

$45.855

+0.36%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.23

+0.69%

Continue in GoAI

Research GELS

research.disclaimer